Loading
institutionsInstitution
Holden Comprehensive Cancer Center, University of Iowa
Iowa's only NCI-designated centre, home to the national neuroendocrine tumour SPORE and pharmacological ascorbate research.
Overview
NCI-designated since 2000, Holden serves the state of Iowa and is the only NCI comprehensive centre between Chicago and Omaha. It holds the NCI's only Specialized Program of Research Excellence dedicated to neuroendocrine tumours, building on decades of somatostatin-receptor work, and offers peptide receptor radionuclide therapy. Its free-radical radiation biology programme has carried high-dose intravenous vitamin C (pharmacological ascorbate) from bench to randomised trials in pancreatic cancer and glioblastoma. The centre also runs a statewide cancer registry and rural outreach programmes.
Location
Iowa City, IA, US
Type
cancer center · University of Iowa
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#113 · 37 points (0 Newsweek + 15 NCI + 22 from 11 linked objects) · ranking
- Neuroendocrine tumour SPORE
- Pharmacological ascorbate
- Radiation biology
Similar pages
- PersonSimron Singh
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Radioligand therapy (beta emitters), Neuroendocrine tumours.
- PersonJonathan R. Strosberg
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Radioligand therapy (beta emitters), Neuroendocrine tumours.
- InstitutionSalk Institute Cancer Center
Shares Metabolic therapy: starving the tumour of a nutrient, NCI-Designated Cancer Centers, National Cancer Institute (NIH), Pancreatic ductal adenocarcinoma.
- InstitutionRutgers Cancer Institute of New Jersey
Shares Metabolic therapy: starving the tumour of a nutrient, NCI-Designated Cancer Centers, Neuroendocrine tumours, National Cancer Institute (NIH).
- PersonEmily K. Bergsland
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Radioligand therapy (beta emitters), Neuroendocrine tumours.
- InstitutionO'Neal Comprehensive Cancer Center at UAB
Shares NCI-Designated Cancer Centers, National Cancer Institute (NIH), Glioma & glioblastoma, Pancreatic ductal adenocarcinoma.
- InstitutionUppsala University Hospital / Uppsala University
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Radioligand therapy (beta emitters), Neuroendocrine tumours.
- CompanyPOINT Biopharma
Shares Somatostatin receptor 2, Radioligand therapy (beta emitters), Neuroendocrine tumours.
cancers
fronts
technologies
targets
drugs
ApprovedRadioligand therapy (beta)
Lutetium-177 dotatate · Lutathera